Back to top

Neurogene price target raised to $81 from $69 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on Neurogene (NGNE) to $81 from $69 and keeps a Buy rating on the shares. Th...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Neurogene Inc. (NGNE)

Taysha Gene Therapies, Inc. (TSHA)